Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC

Dr Giulia Pasello - University of Padova, Padua, Italy
Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC ( Dr Giulia Pasello - University of Padova, Padua, Italy )
17 Apr 2025

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )
10 Apr 2025

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer

Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA
Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer ( Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA )
10 Apr 2025

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC

Dr Sacha Rothschild - University of Basel, Basel, Switzerland
Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC ( Dr Sacha Rothschild - University of Basel, Basel, Switzerland )
10 Apr 2025

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany
Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )
8 Apr 2025

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced

Prof Nicolas Girard - Institut Curie, Paris, France
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced ( Prof Nicolas Girard - Institut Curie, Paris, France )
7 Apr 2025

Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer

Dr Fabian Falkenbach - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer ( Dr Fabian Falkenbach - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
1 Apr 2025

NeuroSAFE-guided RARP improves surgical precision for patients with localised prostate cancer

Prof Greg Shaw - University College Hospital, London, UK
NeuroSAFE-guided RARP improves surgical precision for patients with localised prostate cancer ( Prof Greg Shaw - University College Hospital, London, UK )
1 Apr 2025

The added value of integrative medicine

Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos
The added value of integrative medicine ( Dr Marta Capelan, Dr Beth DuPree and Rosa Olmos )
1 Apr 2025

Urine test could reduce post-op scans for kidney cancer by half

Dr Saeed Dabestani - Lund university, Lund, Sweden
Urine test could reduce post-op scans for kidney cancer by half ( Dr Saeed Dabestani - Lund university, Lund, Sweden )
27 Mar 2025

Micro-ultrasound is as effective as MRI in detecting prostate cancer

Dr Laurence Klotz - Sunnybrook Health Sciences Centre, Toronto, Canada
Micro-ultrasound is as effective as MRI in detecting prostate cancer ( Dr Laurence Klotz - Sunnybrook Health Sciences Centre, Toronto, Canada )
27 Mar 2025

Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada
Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )
27 Mar 2025